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RESULTS

What do we know with ‘Limited Evidence’?
The brain changes seen by imaging
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Adjusted odds ratio for any psychosis outcome according to ever use verses ‘Frequent use’
Influence
on brain development during adolescence
of Cannabis in individual studies at 95% CI
Nature of most toxic metabolite which is psychosis-genic.
Role of CB receptors in schizophrenia and psychosis
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Toxic-Psychotic State’
Adolescent mental health & Cannabissuggest long-term deleterious 4
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predisposing genetic and/or environmental factors

40% to 70%
of
adolescent
s - at least
one drug or
alcohol
problem.
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Schizophrenia

size of
psychosis
"load,"
comorbid
distress and
depression,
cannabis
use
,

Severe
disorder
Threshold of
disorder

Cognition

Mild
Disorder

Low
Early age use , Polydrug abuse, Personality typenonspecific-predisposed social anxiety and dysphoria,
good evidence for comorbidity ASPD-83% Enhance
vulnerability { with OD 29.6, Life Time Prevalence for
cannabis dependence was 14.7% }

Vulnerable

Stress level

Resilient

Vulnerability continuum

Amresh.Shrivastava

15/03/2008

Theresa et al , Lancet, 2007

Comorbidity
Psychosis

With respect to sequencing,
mood and other psychiatric
disorders occur after the
onset of drug-related
problems. .This may not
hold true for schizophrenia,
however, which does
frequently occur in
adolescents., however the
evidence is changing
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 development of therapeutic tools for a variety of neuropsychiatric disorders
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Cannabis
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Gender specific differences.
how cannabinoids influence neurodevelopment

DISCUSSION

Cannon M, Clarke MC.
Risk for schizophrenia--broadening the concepts, pushing back the
boundaries. Schizophr Res. 2005 Nov 1;79(1):5-13.
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Introduction: cannabis continues to affect
mental health. Its abuse is on rise globally.
In Canada a rise by 30% in last ten years
has been observed in high school students.
Interrelationship of cannabis with psychosis
and schizophrenia is a complex one.
Cannabis is highly comorbid with psychosis,
& related to functional disability and
outcome. It poses several challenges in
understanding causal relationship for
comorbidity, underlying neurochemical basis
and specifics of service development.
Prevalence of Cannabis varies from 20 to
50% early psychosis. Objective of this paper
is to review available literature to identify
challenges for newer targets of research and
preventive measures.
Method: Recent literature from electronic
data base search identifies role and
relationship of cannabis and psychosis.
Results. Cannabis is a risk factor for both
psychosis and schizophrenia. & Appears to
have causal relationship for early and laterage psychosis. Mood symptoms are also
significant but less recognized.
Understandings of the process and causes
have significantly advanced with discovery
of cannabinoid receptors and endogenous
cannabinoids. It is clear that cannabis
increases brain vulnerability, causes poorer
outcome and more side effects. Cannabis
causes cognitive dysfunction that perhaps
works as a common denominator for the
risk-vulnerability. It appears to have
independent genetic component related to
disruption in neurotransmission affecting
neuronal plasticity. Much less attention has
been paid in developing services targeted
towards harm reduction and developing
therapeutics.
Conclusion. Cannabis is potential risk factor
for poorer outcome in psychosis. New
biological and social service initiatives will
add value to early psychosis programs
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• Cannabinoids &
immunity/ Glioma

• Cannabinoids &
Neurodegeneration

Huntington's
disease

METHODS AND MATERIALS

Explanation for close relationship between
Psychosis & cannabis is still unclear.
Available evidence for ‘causal relationship’ suggests
only possibilities

Parkinson's
disease

cannabinoid Agonists and antagonists : interrupt 1 of the endocannabinoids.
uptake or metabolism

Abstinence
results in
decreases, and
administration
results in
increases
correlating with
subjective
intoxication.

Findings correlate
partially with
neuropsychologic
al data,

J Neuropsychiatry Clin Neurosci. 2006
Summer;18(3):318-32
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What
therapeutics
can be applied?
What brain
mechanisms
are the
processes?

Subcortex (Amygdala,
Hippocampus & Insular
cortex) Basal regions
(striatum)

Is Cognition
the factor?

These alterations are
associated with abnormal
patterns of activation during
cognitive memory tasks,
inhibition & decision-making
1
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Rev Neurol. 2007 Apr 1-15;44(7):432-9.

Settle the issue of
Cannabis induced
diagnosis
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What are
the
factors?

What is
the
process?
How to
change?
CannabisRelatedPsychosis

To prove that Cannabis increases brain vulnerability
by itself , various evidences are required
It changes cognition in
nature and degree
That there is a
genetic basis for
cannabis induced
Cognitive changes

That there are
biochemical
correlates which
can explain the
change

Cognitive changes are
not dependent upon
genetic liability of
psychosis
That these
changes are
supported by
imaging studies

That
epidemiological &
Clinical studies can
conform
diagnosable
phenotypes
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There is a very strong epidemiological evidence for
correlation/comorbidity.
Cannabis is a risk factor for psychosis, for a
variety of syndromes at later age.
Most users don’t develop Psychosis;
There seems to be no reliable biological
95% of 18 year; 90% of 15 years old; Did not develop at age 26 – Capsi et al
explanation as to why exposure to cannabis should
precipitate psychosis.
THC causes brain effects and influences mental
Two main
Cannabis
E-CB - endo
questions
condition by causing abnormal transmission with
cannabinoid
s provides
dopamine
Explanation
Why Cognition is
There are regional changes in prefrontal cortexForas
significant to
Cognitive
psychosis?
well as sub-cortical regions most of the behavioural
deficits
effects are due to modulation of CB receptors.
What impact can
Cognitive impairment due to cannabis remains
cannabis cause
Cognition
Psychosis
on Cognition?
uncertain and unexplained
Neurobiology of cognition is one of the most challenging in research.
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in
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What causes

??

Deficit
occurs
due to
acute use.

Deficit
only after
a long
time

Deficit is a
conseque
nce of
Cannabis

CONCLUSIONS

Deficit is
conseque
nce of
psychosis

How does the cognitive dysfunction arise?

Knowledge of Neurochemical correlates & exact neuronal mechanism of cognitive
dysfunction continues to be a major limitation in understanding the deficit and
developing therapeutics.
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Structural
abnormalities
generally have not
been identified
with chronic use.

Regular users
demonstrate
reciprocal
changes in brain
activity globally
and in cerebellar
and frontal
regions.

Tremors

Schizophrenia

• Cannabis &
Cognition
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synthesis,

subjective
reports of
impairment
and coping.

Toward a world consensus on prevention of schizophrenia.
Van Os J, Delespaul P.; Dialogues Clin Neurosci. 2005;7(1):53-67.

Brain neuroimaging in
cannabis use indicates
Extensive areas of the
cortex (especially in the
frontal and temporal cortex)

• Cannabis &
Neuro-protection

cognitive
ability,

Risk for transition to full-blown
psychotic disorder
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Potential therapeutic targets
currently under investigation

• Cannabinoids &
Neurogenesis

1

heavy cannabis use in adolescence.

detectable schizophrenia prodromes
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 Predominant questions
& Limitations of available research data
Is cannabis involved in memory impairment?
 Do Cognitive effects (arising from Cannabis) form a ‘risk –factor’ for psychosis?
What are the biochemical correlates of these cognitive changes?
Will cognitive enhancement reduce the risk for psychosis in abusers? Will it be
possible to develop such cognitive enhancers?
Limited data-still needs more political push & more group initiatives in
research of Cannabis and Mental Health.
However there are sufficient pointers to suggest the possibilities and need for
more aggressive research.
.

